{"id":"NCT04501679","sponsor":"Galderma R&D","briefTitle":"A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-11","primaryCompletion":"2022-03-30","completion":"2022-03-31","firstPosted":"2020-08-06","resultsPosted":"2024-07-10","lastUpdate":"2024-07-10"},"enrollment":274,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Prurigo Nodularis"],"interventions":[{"type":"DRUG","name":"Nemolizumab","otherNames":["CD14152"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Nemolizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\\>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.","primaryOutcome":{"measure":"Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16","timeFrame":"Baseline, Week 16","effectByArm":[{"arm":"Nemolizumab","deltaMin":103,"sd":null},{"arm":"Placebo","deltaMin":19,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":74,"countries":["United States","Belgium","Canada","France","Netherlands","Poland","South Korea","Spain","Switzerland"]},"refs":{"pmids":["37888917","40266487"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":183},"commonTop":["Neurodermatitis","Headache","Dermatitis atopic"]}}